This study is for patients with certain types of advanced cancers. It tests a new way to see cancers inside the body using special imaging drugs, **68Ga-DFC413** and **68Ga-NNS309**. These drugs are radioactive and help doctors see tumors better. The study has two parts: the first part checks the safety and how the drug moves in the body, while the second part compares the two drugs.
**Eligibility:** Adults 18+ with specific advanced cancers like pancreatic, lung, certain breast, colorectal, and soft tissue cancers can join. Participants need at least one tumor that can be measured.
**Exclusions:** People with certain health issues or recent surgeries, those who are pregnant or breastfeeding, and individuals with other conditions that might affect the study are not eligible.
**Key Points:**
- Participants will receive a radioactive drug dose and undergo imaging.
- The study may involve more than one visit for imaging purposes.
- Participants must meet specific health criteria to ensure safety.
This study is important to improve cancer imaging, which can help in better treatment planning.
How understandable was the trial content above?
Hard to understand
Easy to understand